GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CERo Therapeutics Holdings CERO · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

-18.66%

Close of 5 Nov 2026, in USD

Analyst ratings

7 analysts, 1 Aug 2026. The analysts' own views, not ours.

  • 0Strong buy
  • 0Buy
  • 4Hold
  • 1Sell
  • 2Strong sell

Price targets

Brokers' own targets, 14 Nov 2025. Not our view.

Average target 30.60

Low
30.30
Average
30.60
Median
30.60
High
31.50

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue———$26.7m$67.2m
Revenue, highest———$54.9m$138.4m
Earnings per share-2.50-3.26-2.82-2.86-2.41
Earnings per share, highest-2.50-3.26-2.90-2.94-2.48
Earnings per share, lowest-2.50-3.26-2.70-2.74-2.31
Analysts01444

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Forecast-0.80-0.80-0.75-0.90-124.26-121.58
Reported-0.54-0.20-0.75-3.44-61.71-28.80
Difference+32.1%+75.0%0.0%-283.2%+50.3%+76.3%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth 0.0% a year over 10 years. Return on equity 365.7%.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.